FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to a method for detecting an inflammatory component that promotes tumor growth in initial choroidal melanoma where the level of CC chemokines (CCL2 / MCP-1, CCL3 / MIP-1α) and of CXC chemokines (CXCL12 / SDF- 1α) is determined in the lacrimal fluid of both eyes. With an increase in each of them in each of the eyes more than 4 times in comparison with the norm, an inflammatory component is revealed that promotes tumor growth.
EFFECT: invention provides timely, adequate tactics for the treatment of initial choroidal melanoma.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR THE DIFFERENTIAL DIAGNOSIS OF MELANOMA OF THE CHOROID OF THE CENTRAL LOCALIZATION AND THE LATE STAGE OF AGE-RELATED MACULAR DEGENERATION | 2022 |
|
RU2792554C1 |
| ANTIKINE ANTIBODIES BINDING TO SEVERAL CC-CHEMOKINES | 2010 |
|
RU2574786C2 |
| METHOD FOR INCREASING THE PROLIFERATIVE POTENTIAL OF THREE-DIMENSIONAL TUMOR CELL CULTURES | 2021 |
|
RU2782600C1 |
| METHOD FOR PREDICTING THE LETHAL OUTCOME IN PATIENTS WITH SEVERE CoVID-19 | 2021 |
|
RU2780748C1 |
| IMPROVED COMPOSITION FOR INHIBITION OF TUMOUR CELL PROLIFERATION | 2011 |
|
RU2565542C2 |
| USING MOLECULAR MARKERS IL-3, IL-33 AND IL12Ρ40 TO CHARACTERIZE SEVERITY OF RESPIRATORY INFECTIONS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS AND HUMAN METAPNEUMOVIRUS | 2016 |
|
RU2707549C2 |
| METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 1999 |
|
RU2157998C1 |
| MCP-1 BINDING NUCLEIC ACIDS | 2007 |
|
RU2518330C2 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| MCP-1 BINDING NUCLEIC ACID AND USING IT | 2008 |
|
RU2542973C2 |
